Easy-to-use clinical tool for survival estimation in Ewing sarcoma at diagnosis and after surgery

被引:0
作者
S. E. Bosma
C. Lancia
A. J. Rueten-Budde
A. Ranft
H. Gelderblom
M. Fiocco
M. A. J. van de Sande
P. D. S. Dijkstra
U. Dirksen
机构
[1] Leiden University Medical Center,
[2] department of orthopedics,undefined
[3] Leiden University Mathematical Institute,undefined
[4] University Hospital Essen,undefined
[5] University Duisburg. Essen,undefined
[6] Pediatrics III,undefined
[7] Sarcoma Centre,undefined
[8] West German Cancer Centre,undefined
[9] German Cancer Consortium,undefined
[10] Leiden University Medical Center,undefined
[11] department of medical oncology,undefined
[12] Leiden University Medical Center,undefined
[13] medical statistics/biomedical data sciences,undefined
[14] German Cancer Consortium (DKTK),undefined
来源
Scientific Reports | / 9卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Accurate survival estimations in Ewing sarcoma are necessary to develop risk- and response adaptive treatment strategies allowing for early decision-making. We aim to develop an easy-to-use survival estimation tool from diagnosis and surgery. A retrospective study of 1314 Ewing sarcoma patients was performed. Associations between prognostic variables at diagnosis/surgery and overall survival (OS), were investigated using Kaplan-Meier and multivariate Cox models. Predictive accuracy was evaluated by cross-validation and Harrell C-statistics. Median follow-up was 7.9 years (95%CI 7.6–8.3). Independent prognostic factors at diagnosis were age, volume, primary tumor localization and disease extent. 5 risk categories (A-E) were identified with 5-year OS of 88% (86–94), 69% (64–74), 57% (50–64), 51% (42–60) and 28% (22–34) respectively. Harrell C-statistic was 0.70. Independent prognostic factors from surgery were age, volume, disease extent and histological response. In categories A-B, 5y OS increased to 92% (87–97) and 79% (71–87) respectively for 100% necrosis and decreased to 76% (67–85) and 62% (55–69) respectively for <100% necrosis. In categories C-E, 5y OS increased to 65% (55–75), 65% (52–78) and 52% (38–66) respectively for ≥90% necrosis and decreased to 38% (22–54), 11% (0–26) and 7% (0–19) respectively for <90% necrosis. We present an easy-to-use survival estimation tool from diagnosis in Ewing sarcoma based on age, volume, primary tumor localization and disease extent. Histological response is a strong additional prognostic factor for OS.
引用
收藏
相关论文
共 70 条
[1]  
Ladenstein R(2010)Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial J Clin Oncol 28 3284-3291
[2]  
Haeusler J(2010)The value of local treatment in patients with primary, disseminated, multifocal Ewing sarcoma (PDMES) Cancer 116 443-450
[3]  
Grunewald TGP(2018)Ewing sarcoma Nat Rev Dis Primers 4 5-179
[4]  
Pappo AS(2018)Rhabdomyosarcoma, Ewing Sarcoma, and Other Round Cell Sarcomas J Clin Oncol 36 168-553
[5]  
Dirksen U(2011)Risk of recurrence and survival after relapse in patients with Ewing sarcoma Pediatr Blood Cancer 57 549-4362
[6]  
Stahl M(2005)Survival after recurrence of Ewing’s sarcoma family of tumors J Clin Oncol 23 4354-384
[7]  
Barker LM(2007)Analysis of prognostic factors in ewing sarcoma family of tumors: review of St. Jude Children’s Research Hospital studies Cancer 110 375-1659
[8]  
Pendergrass TW(2003)Therapy and survival after recurrence of Ewing’s tumors: the Rizzoli experience in 195 patients treated with adjuvant and neoadjuvant chemotherapy from 1979 to 1997 Ann Oncol 14 1654-29
[9]  
Sanders JE(2016)The accuracy of clinicians’ predictions of survival in advanced cancer: a review Ann Palliat Med 5 22-689
[10]  
Hawkins DS(2015)Developing a prognostic model for localized Ewing sarcoma family of tumors: A single institutional experience of 224 cases treated with uniform chemotherapy protocol J Surg Oncol 111 683-53